News

Fierce Biotech2h
Smiths Medical recalls infusion pumps over false alarm, 2 other potential safety issues
Smiths Medical also identified three issues associated with the potential for thermal damage in affected infusion pumps. If ...
Fierce Biotech1h
Seyltx reserves option to boost chronic cough pipeline with 8 GluN2B antagonists
The widely used cough suppressant dextromethorphan is an NMDA receptor antagonist. Seyltx and Atlanta-based NeurOp are ...
Fierce Biotech3h
Chasing Sarepta, RegenXBio links DMD gene therapy to improved outcomes
RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...
Fierce Biotech3h
Corcept unveils promising survival data from failed phase 2 ALS trial
Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...
Fierce Biotech7h
Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T-cell engager
Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T cell engager that the biotech plans to pair ...
Fierce Biotech19h
Rapt Therapeutics cuts staff for 2nd time in less than a year, continuing fallout from FDA hold
Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following ...
Fierce Biotech23h
With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer field
As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...